Typicality: | 0.365 |
Saliency: | 0.269 |
in august | 4 | temporal |
at each investigative site | 3 | location |
in approximately 20 years | 2 | temporal |
trial → be approved by → the fda | 12 |
trial → be cleared by → the fda | 4 |
negative | neutral | positive |
0.137 | 0.630 | 0.233 |
Raw frequency | 16 |
Normalized frequency | 0.269 |
Modifier score | 0.500 |
Perplexity | 289.463 |